Lys558

Site Information
LLSEFPDkFGsCVPH SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3933139

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 )
Relevant cell line - cell type - tissue:	brain ( 2 , 13 ) , pooled tissues ( 2 )

Downstream Regulation
Effects of modification on PSD-95:	molecular association, regulation ( 1 )
Effects of modification on biological processes:	cytoskeletal reorganization ( 1 ) , neural plasticity ( 1 )
Induce interaction with:	AKAP1 (mouse) ( 1 ) , GKAP1 (mouse) ( 1 ) , SPAAR (human) ( 1 )

References
1	Ma Q, et al. (2017) Proteasome-independent polyubiquitin linkage regulates synapse scaffolding, efficacy, and plasticity. Proc Natl Acad Sci U S A 114, E8760-E8769 28973854 Curated Info
2	Wagner SA, et al. (2012) Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics 11, 1578-85 22790023 Curated Info
3	Guo A (2008) CST Curation Set: 4120; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
4	Guo A (2008) CST Curation Set: 4121; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
5	Guo A (2008) CST Curation Set: 4122; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
6	Guo A (2008) CST Curation Set: 4123; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
7	Guo A (2008) CST Curation Set: 4124; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
8	Guo A (2008) CST Curation Set: 4125; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
9	Guo A (2008) CST Curation Set: 4126; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
10	Guo A (2008) CST Curation Set: 4127; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
11	Guo A (2008) CST Curation Set: 4128; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
12	Guo A (2008) CST Curation Set: 4129; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: Alzheimer's disease; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
13	Guo A (2007) CST Curation Set: 3117; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info